

IN THE CLAIMS

Please add new claims 12 and 13 as follows:

O 2

Rule
124

(13)
D2

1214

(New) The pharmaceutical preparation according to claim 6, wherein the further cytostatic agent is cisplatin, methotrexate, aminopterin, dcarbazine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, or mitomycin C.

15

(New) The use according to claim 10, wherein said cancerous disease is selected from testicular tumors, ovarian carcinomas, bladder carcinomas, colonic carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervical and endometrial carcinomas, sarcomas, melanomas and leukemias.

With this Amendment, new claims 12 and 13 are added. Claim 12 is based on the third full paragraph on page 8 of the specification. Claim 13 is based on the third full paragraph on page 5 of the specification. Thus, no new matter is added by new claims 12 and 13.

Applicants submit that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' attorney would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney of record.

Date: May 2, 2002

Respectfully submitted,

Name: David J. Dykeman
Registration No.: 46,678
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100